The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
 
Atish Dipankar Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Astellas Pharma; Bayer; Janssen
Research Funding - Bayer; Janssen (Inst)
Travel, Accommodations, Expenses - Genentech
 
Wanling Xie
Consulting or Advisory Role - Bayer
 
Mamta Parikh
Consulting or Advisory Role - Exelixis; Janssen
 
Daniel Lee
No Relationships to Disclose
 
Elizabeth R. Kessler
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Medivation/Astellas; Pfizer (Inst)
 
David Johnson Einstein
Research Funding - Bristol-Myers Squibb (Inst); Trovagene (Inst)
 
Bose Kochupurakkal
Employment - Amgen (I)
Stock and Other Ownership Interests - Amgen (I)
Research Funding - Lilly (Inst)
 
Kent William Mouw
Consulting or Advisory Role - EMD Serono; Pfizer
Research Funding - Pfizer
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Microsoft; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
L. Austin Doyle
Patents, Royalties, Other Intellectual Property - I receive royalties for a patent related to cloning and characterizing the ABCG2 transporter. This patent is administered through the University of Maryland School of Medicine. The patent has nothing to do with my current work or any work in ASCO abstrac
 
Alan D. D'Andrea
Stock and Other Ownership Interests - Ideaya, Inc.
Honoraria - Lilly; Sanofi
Consulting or Advisory Role - Biomarin; Deerfield Management; Ideaya, Inc.; Intellia Therapeutics; Third Rock Ventures; Vertex
Travel, Accommodations, Expenses - Biomarin; IDEAYA Biosciences; Lilly
 
Mary-Ellen Taplin
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Merck; Pfizer; Progenics; Research to Practice; UpToDate
Consulting or Advisory Role - AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Astex Pharmaceuticals; Bayer; Bicycle Therapeutics; Cybrexa Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); CanBas (Inst); Cellceutix (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology